Clinical and Molecular Hepatology (대한간학회지)

The Korean Association for the Study of the Liver (대한간학회)
권호 표지

Changes in liver stiffness during the course of acute hepatitis A

급성 A형간염에 의한 간내 강성도의 변화

Seo, Yeon-Seok;Um, Soon-Ho;Suh, Sang-Jun;Jung, Eun-Suk;Jang, Jin-Su;Kwon, Yong-Dae;Park, Sang-Hoon;Keum, Bo-Ra;Kim, Yong-Sik;Jeen, Yoon-Tae;Chun, Hoon-Jai;Kim, Chang-Duck;Ryu, Ho-Sang
서연석;엄순호;서상준;정은석;장진수;권용대;박상훈;금보라;김용식;진윤태;전훈재;김창덕;류호상

  • Published : 20080000
⟨ Previous Next ⟩

Abstract

Backgrounds/Aims: In some patients with chronic hepatitis, liver stiffness (LS) findings do not reflect fibrosis stage. This study was performed to evaluate whether acute liver inflammation could influence LS findings. Methods: Patients with acute hepatitis A admitted to our hospital were included. Hepatitis was classified on admission using serum ALT and bilirubin levels as inflammation phase, jaundice phase, or recovery phase. Patients who admitted during the recovery phase (whose ALT and bilirubin levels fell continuously during hospitalization) and therefore, their peak-ALT and peak bilirubin levels could not be determined were exduded. Enrolled patients underwent FibroScan during hospitalization and after discharge. Results: Seventy-six patients with acute hepatitis A were enrolled (median age, 29 years; 46 men and 30 women). Among them, 33 (43.4%) and 43 (56.6%) patients were admitted during the inflammation phase and jaundice phase, respectively. For patients admitted during the inflammation phase, mean (±SD) time from symptom-onset day to maximum ALT level was 7 (±3) days. For all patients, mean time from symptom- onset to maximum bilirubin level was 11 (±4) days. Mean LS during admission was 8.9 (±3.3) kPa (median, 8.4 kPa). LS was significantly correlated with serum bilirubin level, which was the only factor found to be significantly associated with the increased LS (>7.08 kPa). In all patients, LS increased gradually from the symptom-onset and peaked at 8-9 days later. Conclusions: Severe hepatic inflammation can affect the LS findings and thus, care is required when assessing fibrosis stage using LS measurement in patients with severe inflammation. (Korean J Hepatol 2008;14:465-473)

목적: 만성 간염 환자에서 liver stiffness (LS) 측정이 간섬유화를 평가하는 데 매우 유용한 검사로 알려져 있으나, 일부 환자에서는 LS와 실제 간섬유화 단계 사이에 상당한 차이가 관찰된다. 본 연구는 간의 괴사염증 정도가 이런 두 검사 결과 사이의 차이에 관여하는가를 평가하기 위해 시행하였다. 대상과 방법: 급성 A형간염으로 본원에 입원한 환자를 대상으로 하였다. 입원 후 환자의 혈청 ALT 수치와 bilirubin 수치의 변화에 따라 환자의 입원 당시 급성 A형간염의 단계를 염증단계, 황달단계 및 회복단계로 분류하였으며, 회복단계에서 입원한 환자(입원 후 ALT 및 bilirubin 수치가 계속 감소하는 경우)는 본 연구에서 제외하였다. 입원 시 LS를 측정하였으며 상태가 호전되어 퇴원한 후 추적하였다. LS값과 급성 A형간염의 진행단계, LS 측정 당시의 혈청 AST, ALT 및 bilirubin 수치와의 상관관계를 분석하였다. 결과: 76명의 급성 A형간염 환자가 본 연구에 포함되었으며 연령의 중앙값은 29세였다(남자 46명 여자 30명). 이들 중 33명(43.4%)은 염증단계에, 43명(56.6%)은 황달단계에 입원하였다. 염증단계에 입원한 33명에서 급성 A형간염의 증상이 발생한 후 혈청 ALT가 최고치에 도달할 때까지의 기간은 7±3일이었으며, 전체 대상 환자에서 증상이 발생한 후 bilirubin이 최고치에 도달할 때까지의 기간은 11±4일이었다. 입원 중 측정한 LS값은 8.9±3.3 kPa였다. LS값은 bilirubin 수치와만 상관관계를 보였으며, LS 상승(>7.08 kPa)과 관련이 있는 인자도 bilirubin 수치뿐이었다. 급성 간염의 증상이 발생한 후 LS값은 점차 상승하다가 증상 발생 후 8~9일 정도에 최고치에 도달한 후 점차 감소하였다. 결론: 심한 간의 괴사염증은 LS를 높여 간섬유화 단계를 실제보다 과대평가할 수 있으므로 급성 악화를 동반한 만성간염 환자에서 LS를 측정한 경우 결과의 판정에 유의하여야 할 것으로 생각된다.

Keywords

References

  1. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003;362:2095-2100 https://doi.org/10.1016/S0140-6736(03)15109-4
  2. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002;36(Suppl 1):S152-S160 https://doi.org/10.1002/hep.1840360720
  3. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the group of epidemiology of the French association for the study of the liver (AFEF). Hepatology 2000;32:477-481 https://doi.org/10.1053/jhep.2000.16602
  4. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500 https://doi.org/10.1056/NEJM200102153440706
  5. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;39:239-244 https://doi.org/10.1016/S0168-8278(03)00191-0
  6. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-1457 https://doi.org/10.1016/j.hep.2003.09.022
  7. Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol 2003;38:427-432 https://doi.org/10.1080/00365520310000825
  8. Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986;1:523-525
  9. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-2618 https://doi.org/10.1111/j.1572-0241.2002.06038.x
  10. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR cooperative study group. Hepatology 1994;20:15-20 https://doi.org/10.1002/hep.1840200104
  11. Afdhal NH. Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology 2003;37:972-974 https://doi.org/10.1053/jhep.2003.50223
  12. Colletta C, Smirne C, Fabris C, Toniutto P, Rapetti R, Minisini R, et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005;42:838-845 https://doi.org/10.1002/hep.20814
  13. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-1713 https://doi.org/10.1016/j.ultrasmedbio.2003.07.001
  14. Coco B, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007;14:360-369 https://doi.org/10.1111/j.1365-2893.2006.00811.x
  15. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350 https://doi.org/10.1053/j.gastro.2004.11.018
  16. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54 https://doi.org/10.1002/hep.20506
  17. Nahon P, Thabut G, Ziol M, Htar MT, Cesaro F, Barget N, et al. Liver stiffness measurement versus clinicians' prediction or both for the assessment of liver fibrosis in patients with chronic hepatitis C. Am J Gastroenterol 2006;101:2744-2751 https://doi.org/10.1111/j.1572-0241.2006.00816.x
  18. Gomez-Dominguez E, Mendoza J, Rubio S, Moreno-Monteagudo JA, Garcia-Buey L, Moreno-Otero R. Transient elastography: a valid alternative to biopsy in patients with chronic liver disease. Aliment Pharmacol Ther 2006;24:513-518 https://doi.org/10.1111/j.1365-2036.2006.02999.x
  19. Ganne-Carrie N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, Castera L, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006;44:1511-1517 https://doi.org/10.1002/hep.21420
  20. Corpechot C, El Naggar A, Poujol-Robert A, Ziol M, Wendum D, Chazouilleres O, et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006;43:1118-1124 https://doi.org/10.1002/hep.21151
  21. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006;55:403-408 https://doi.org/10.1136/gut.2005.069153
  22. de Ledinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006;41:175-179 https://doi.org/10.1097/01.qai.0000194238.15831.c7
  23. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003;38:481-492
  24. Arena U, Vizzutti F, Corti G, Ambu S, Stasi C, Bresci S, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008;47:380-384 https://doi.org/10.1002/hep.22007
  25. Sagir A, Erhardt A, Schmitt M, Haussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008;47:592-595 https://doi.org/10.1002/hep.22056
  26. Roulot D, Czernichow S, Le Clesiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 2008;48:606-613 https://doi.org/10.1016/j.jhep.2007.11.020
  27. Ferrell LD, Theise ND, Scheuer PJ. Acute and chronic viral hepatitis. In: MacSween RNM, Burt AD, Portmann BC, Ishak KG, Scheuer PJ, Anthony PP, eds. Pathology of the Liver. 14th ed. London: Chruchill Livingstone, 2002:313-362